{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:38:17Z","timestamp":1792733897572,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The aim of this study is to evaluate the application, methodology and consistency of utility values used in National Institute for Health and Care Excellence (NICE) single technology appraisals (STAs) of targeted therapies for advanced or metastatic non-small-cell lung cancer (NSCLC) over the past decade.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A review was conducted of NICE STAs of NSCLC targeted therapies from 2012 to 2022, focusing on four key aspects: (1) utility values per health state as defined by the economic model structure; 2) the primary sources of these utility values; (3) the methods used to derive utilities for quality of life, and 4) the application of disutilities or utility decrements.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the included 16 appraisals for targeted therapies, substantial variation was identified in the application, methodology, and consistency of utility values used in CUAs appraised by NICE over the past decade. Most appraisals used health state-specific utilities, with progression free values primarily derived from clinical trials and progressed disease values more often derived from external literature. Disutilities for adverse events were applied in an inconsistent way and no stratification by age was reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Enhancing methodological consistency and incorporating up-to-date, representative utility data, particularly for progressed disease and adverse events, would strengthen the robustness, transparency and comparability of NICE technology appraisals of targeted therapies in NSCLC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10198-026-01954-z","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:51:00Z","timestamp":1792731060000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Approaches to utility value assessment in NICE technology appraisals of targeted therapies for non-small-cell lung cancer: a critical examination and recommendations"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9515-1044","authenticated-orcid":false,"given":"Lotte","family":"Westerink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6306-3653","authenticated-orcid":false,"given":"Maarten Jacobus","family":"Postma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2368-2262","authenticated-orcid":false,"given":"Job Frank Frank","family":"van Boven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1190-2638","authenticated-orcid":false,"given":"Cornelis","family":"Boersma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"issue":"10","key":"1954_CR1","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.jval.2023.05.015","volume":"26","author":"A Angelis","year":"2023","unstructured":"Angelis, A., M. Harker, J. Cairns, M.K. Seo, R. Legood, A. Miners, et al. 2023. The evolving nature of health technology assessment: A critical appraisal of NICE\u2019s new methods manual. Value in Health 26 (10): 1503\u20139. https:\/\/doi.org\/10.1016\/j.jval.2023.05.015.","journal-title":"Value in Health"},{"key":"1954_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12103372","author":"D Armocida","year":"2023","unstructured":"Armocida, D., A. Pesce, M. Palmieri, F. Cofano, G. Palmieri, P. Cassoni, et al. 2023. EGFR-driven mutation in non-small-cell lung cancer (NSCLC) influences the features and outcome of brain metastases. Journal of Clinical Medicine. https:\/\/doi.org\/10.3390\/jcm12103372.","journal-title":"Journal of Clinical Medicine"},{"key":"1954_CR3","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.lungcan.2017.09.011","volume":"113","author":"Y Ben Bouazza","year":"2017","unstructured":"Bouazza, Y Ben, I. Chiairi, O. El Kharbouchi, L. De Backer, G. Vanhoutte, A. Janssens, et al. 2017. Patient-reported outcome measures (PROMs) in the management of lung cancer: A systematic review. Lung Cancer 113: 140\u201351. https:\/\/doi.org\/10.1016\/j.lungcan.2017.09.011.","journal-title":"Lung Cancer"},{"issue":"31","key":"1954_CR4","doi-asserted-by":"publisher","first-page":"3592","DOI":"10.1200\/JCO.20.00505","volume":"38","author":"DR Camidge","year":"2020","unstructured":"Camidge, D. R., H. R. Kim, M. J. Ahn, J. C. H. Yang, J. Y. Han, and M. J. Hochmair et al. 2020. Brigatinib versus crizotinib in advanced ALK inhibitor-naive alk-positive non-small cell lung cancer: second interim analysis of the phase III ALTA-1L trial. Journal Of Clinical Oncology 38(31):3592\u20133603. 10.1200. \/JCO.20.00505 PubMed PMID: 32780660.","journal-title":"Journal Of Clinical Oncology"},{"key":"1954_CR5","unstructured":"Cancer Research, U. K. Lung Cancer Statistics [Internet]. [cited 2025 May 14]. Available from: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/lung-cancer#heading-Zero"},{"issue":"8","key":"1954_CR6","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1097\/JTO.0000000000000232","volume":"9","author":"YF Chen","year":"2014","unstructured":"Chen, Y.F., M.S. Hsieh, S.G. Wu, Y.L. Chang, J.Y. Shih, Y.N. Liu, et al. 2014. Clinical and the prognostic characteristics of lung adenocarcinoma patients with ROS1 fusion in comparison with other driver mutations in East Asian populations. Journal of Thoracic Oncology 9 (8): 1171\u20139. https:\/\/doi.org\/10.1097\/JTO.0000000000000232.","journal-title":"Journal of Thoracic Oncology"},{"key":"1954_CR7","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2147\/CLEP.S69718","volume":"6","author":"PL Chia","year":"2014","unstructured":"Chia, P.L., P. Mitchell, A. Dobrovic, and T. John. 2014. Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. Clinical Epidemiology 6: 423\u201332. https:\/\/doi.org\/10.2147\/CLEP.S69718.","journal-title":"Clinical Epidemiology"},{"issue":"8","key":"1954_CR8","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1097\/JTO.0b013e318299243b","volume":"8","author":"C Chouaid","year":"2013","unstructured":"Chouaid, C., J. Agulnik, E. Goker, G.J.M. Herder, J.F. Lester, J. Vansteenkiste, et al. 2013. Health-related quality of life and utility in patients with advanced non-small-cell lung cancer: A prospective cross-sectional patient survey in a real-world setting. Journal of Thoracic Oncology 8 (8): 997\u20131003. https:\/\/doi.org\/10.1097\/JTO.0b013e318299243b.","journal-title":"Journal of Thoracic Oncology"},{"issue":"10","key":"1954_CR9","doi-asserted-by":"publisher","first-page":"e582","DOI":"10.1016\/S1470-2045(19)30335-3","volume":"20","author":"MH Fiero","year":"2019","unstructured":"Fiero, M.H., J.K. Roydhouse, J. Vallejo, B.L. King-Kallimanis, P.G. Kluetz, and R. Sridhara. 2019. US Food and Drug Administration review of statistical analysis of patient-reported outcomes in lung cancer clinical trials approved between January, 2008, and December, 2017. Lancet Oncology 20 (10): e582\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(19)30335-3.","journal-title":"Lancet Oncology"},{"issue":"12","key":"1954_CR10","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/S1470-2045(16)30508-3","volume":"17","author":"G Goss","year":"2016","unstructured":"Goss, G., C.M. Tsai, F.A. Shepherd, L. Bazhenova, J.S. Lee, G.C. Chang, et al. 2016. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): A multicentre, open-label, single-arm, phase 2 study. Lancet Oncology 17 (12): 1643\u201352. https:\/\/doi.org\/10.1016\/S1470-2045(16)30508-3.","journal-title":"Lancet Oncology"},{"issue":"4","key":"1954_CR11","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","volume":"34","author":"LE Hendriks","year":"2023","unstructured":"Hendriks, L.E., K.M. Kerr, J. Menis, T.S. Mok, U. Nestle, A. Passaro, et al. 2023. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Annals of Oncology 34 (4): 358\u201376. https:\/\/doi.org\/10.1016\/j.annonc.2022.12.013.","journal-title":"Annals of Oncology"},{"key":"1954_CR12","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez Alava, M., A. Wailoo, and S. Pudney et al. Mapping clinical outcomes to generic preference-based outcome measures: development and comparison of methods. Southampton (UK): NIHR Journals Library; [Internet]. 2020 Jun [cited 2024 Jul 25];24(34). Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK558783\/","DOI":"10.3310\/hta24340"},{"issue":"7","key":"1954_CR13","doi-asserted-by":"publisher","first-page":"e006733","DOI":"10.1136\/bmjopen-2014-006733","volume":"5","author":"I Khan","year":"2015","unstructured":"Khan, I., S. Morris, A. Hackshaw, and S. M. Lee. 2015. Cost-effectiveness of first-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy. British Medical Journal Open 5(7):e006733. https:\/\/doi.org\/10.1136\/bmjopen-2014-006733 . PubMed PMID: 26137881.","journal-title":"British Medical Journal Open"},{"issue":"22","key":"1954_CR14","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1200\/JCO.2016.71.5904","volume":"35","author":"DW Kim","year":"2017","unstructured":"Kim, D.W., M. Tiseo, M.J. Ahn, K.L. Reckamp, K.H. Hansen, S.W. Kim, et al. 2017. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: A randomized, multicenter phase II trial. Journal of Clinical Oncology 35 (22): 2490\u20138. https:\/\/doi.org\/10.1200\/JCO.2016.71.5904.","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"1954_CR15","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.cllc.2016.12.015","volume":"18","author":"C Labb\u00e9","year":"2017","unstructured":"Labb\u00e9, C., Y. Leung, J.G. Silva Lemes, E. Stewart, C. Brown, A.P. Cosio, et al. 2017. Real-world EQ5D health utility scores for patients with metastatic lung cancer by molecular alteration and response to therapy. Clinical Lung Cancer 18 (4): 388\u2013395.e4. https:\/\/doi.org\/10.1016\/j.cllc.2016.12.015.","journal-title":"Clinical Lung Cancer"},{"issue":"9","key":"1954_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta18090","volume":"18","author":"L Longworth","year":"2014","unstructured":"Longworth, L., Y. Yang, T. Young, B. Mulhern, M. Hern\u00e1ndez Alava, C. Mukuria, et al. 2014. Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: A systematic review, statistical modelling and survey. Health Technology Assessment 18 (9): 1\u2013224. https:\/\/doi.org\/10.3310\/hta18090.","journal-title":"Health Technology Assessment"},{"key":"1954_CR17","unstructured":"MacMillan Cancer Support. Lung cancer and somatic variants [Internet]. [cited 2025 May 26]. Available from: https:\/\/www.macmillan.org.uk\/healthcare-professionals\/innovation-in-cancer-care\/genomics-toolkit\/lung\/lung-cancer-and-somatic-variants#:~:text=ROS1%20fusions%20are%20present%20in,slightly%20more%20common%20in%20women"},{"issue":"7","key":"1954_CR18","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"TS Mok","year":"2017","unstructured":"Mok, T.S., Y.L. Wu, M.J. Ahn, M.C. Garassino, H.R. Kim, S.S. Ramalingam, et al. 2017. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. New England Journal of Medicine 376 (7): 629\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1612674.","journal-title":"New England Journal of Medicine"},{"key":"1954_CR19","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1477-7525-6-84","volume":"6","author":"B Nafees","year":"2008","unstructured":"Nafees, B., M. Stafford, S. Gavriel, S. Bhalla, and J. Watkins. 2008. Health state utilities for non small cell lung cancer. Health and Quality of Life Outcomes 6: 84. https:\/\/doi.org\/10.1186\/1477-7525-6-84.","journal-title":"Health and Quality of Life Outcomes"},{"issue":"6","key":"1954_CR20","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.jval.2024.02.013","volume":"27","author":"MW Njoroge","year":"2024","unstructured":"Njoroge, M.W., M. Walton, and R. Hodgson. 2024. Understanding the National Institute for Health and Care Excellence severity premium: Exploring its implementation and the implications for decision making and patient access. Value in Health 27 (6): 730\u20136. https:\/\/doi.org\/10.1016\/j.jval.2024.02.013.","journal-title":"Value in Health"},{"key":"1954_CR21","unstructured":"NICE. nice.org.uk [Internet]. 2016 [cited 2022 Jan 27]. Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer; Technology appraisal guidance [TA406]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta406"},{"key":"1954_CR22","unstructured":"NICE. nice.org.uk [Internet]. 2016 [cited 2022 Jan 27]. Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer; Technology appraisal guidance [TA422]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta422"},{"key":"1954_CR23","unstructured":"NICE. nice.org.uk [Internet]. 2018 [cited 2022 Jan 27]. Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer; Technology appraisal guidance [TA529]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta529"},{"key":"1954_CR24","unstructured":"NICE. nice.org.uk [Internet]. 2018 [cited 2022 Jan 27]. Ceritinib for untreated ALK-positive non-small-cell lung cancer; Technology appraisal guidance [TA500]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta500"},{"key":"1954_CR25","unstructured":"NICE. nice.org.uk [Internet]. 2018 [cited 2022 Jan 27]. Alectinib for untreated ALK-positive advanced non-small-cell lung cancer; Technology appraisal guidance [TA536]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta536"},{"key":"1954_CR26","unstructured":"NICE. nice.org.uk [Internet]. 2020 [cited 2022 Jan 27]. Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer; Technology appraisal guidance [TA653]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta653"},{"key":"1954_CR27","unstructured":"NICE. nice.org.uk [Internet]. 2020 [cited 2022 Jan 27]. Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer; Technology appraisal guidance [TA628]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta628"},{"key":"1954_CR28","unstructured":"NICE. NICE real-world evidence framework [Internet]. 2022. Jun [cited 2025 May 22]. Available from: www.nice.org.uk\/corporate\/ecd9"},{"key":"1954_CR29","unstructured":"NICE process and Methods. NICE health technology evaluations: the manual [Internet]. 2022 Jan [cited 2023 Feb 8]. Available from: https:\/\/www.nice.org.uk\/process\/pmg36"},{"issue":"1","key":"1954_CR30","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12955-018-0994-8","volume":"16","author":"N Paracha","year":"2018","unstructured":"Paracha, N., A. Abdulla, and K.S. MacGilchrist. 2018. Systematic review of health state utility values in metastatic non-small cell lung cancer with a focus on previously treated patients. Health and Quality of Life Outcomes 16 (1): 179. https:\/\/doi.org\/10.1186\/s12955-018-0994-8.","journal-title":"Health and Quality of Life Outcomes"},{"key":"1954_CR31","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.2147\/OTT.S100685","volume":"9","author":"J Polanski","year":"2016","unstructured":"Polanski, J., B. Jankowska-Polanska, J. Rosinczuk, M. Chabowski, and A. Szymanska-Chabowska. 2016. Quality of life of patients with lung cancer. OncoTargets and Therapy 9: 1023\u20138. https:\/\/doi.org\/10.2147\/OTT.S100685.","journal-title":"OncoTargets and Therapy"},{"issue":"1","key":"1954_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-12-35","volume":"12","author":"I Proskorovsky","year":"2014","unstructured":"Proskorovsky, I., P. Lewis, C.D. Williams, K. Jordan, C. Kyriakou, J. Ishak, et al. 2014. Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma. Health and Quality of Life Outcomes 12 (1): 35. https:\/\/doi.org\/10.1186\/1477-7525-12-35.","journal-title":"Health and Quality of Life Outcomes"},{"issue":"2","key":"1954_CR33","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S1470-2045(13)70586-2","volume":"15","author":"M Reck","year":"2014","unstructured":"Reck, M., R. Kaiser, A. Mellemgaard, J.Y. Douillard, S. Orlov, M. Krzakowski, et al. 2014. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): A phase 3, double-blind, randomised controlled trial. Lancet Oncology 15 (2): 143\u201355. https:\/\/doi.org\/10.1016\/S1470-2045(13)70586-2.","journal-title":"Lancet Oncology"},{"issue":"7","key":"1954_CR34","doi-asserted-by":"publisher","first-page":"A650","DOI":"10.1016\/j.jval.2014.08.2364","volume":"17","author":"A Roughley","year":"2014","unstructured":"Roughley, A., E. Damonte, G. Taylor-Stokes, A. Rider, and V.C. Munk. 2014. Impact of brain metastases on quality of life and estimated life expectancy in patients with advanced non-small cell lung cancer. Value in Health 17 (7): A650. https:\/\/doi.org\/10.1016\/j.jval.2014.08.2364.","journal-title":"Value in Health"},{"issue":"3","key":"1954_CR35","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1001\/jamaoncol.2015.4482","volume":"2","author":"AG Sacher","year":"2016","unstructured":"Sacher, A.G., S.E. Dahlberg, J. Heng, S. Mach, P.A. J\u00e4nne, and G.R. Oxnard. 2016. Association between younger age and targetable genomic alterations and prognosis in non-small-cell lung cancer. JAMA Oncology 2 (3): 313\u201320. https:\/\/doi.org\/10.1001\/jamaoncol.2015.4482.","journal-title":"JAMA Oncology"},{"issue":"23","key":"1954_CR36","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","volume":"371","author":"BJ Solomon","year":"2014","unstructured":"Solomon, B.J., T. Mok, D.W. Kim, Y.L. Wu, K. Nakagawa, T. Mekhail, et al. 2014. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. New England Journal of Medicine 371 (23): 2167\u201377. https:\/\/doi.org\/10.1056\/NEJMoa1408440.","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"1954_CR37","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2020","unstructured":"Sung, H., J. Ferlay, R.L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, et al. 2020. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 71 (3): 209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"6","key":"1954_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1288","volume":"3","author":"A Tarigopula","year":"2020","unstructured":"Tarigopula, A., G. Ramasubban, V. Chandrashekar, P. Govindasami, and C. Chandran. 2020. EGFR mutations and ROS1 and ALK rearrangements in a large series of non-small cell lung cancer in South India. Cancer Reports 3 (6): e1288. https:\/\/doi.org\/10.1002\/cnr2.1288.","journal-title":"Cancer Reports"},{"key":"1954_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00715","volume":"9","author":"L Van Der Weijst","year":"2019","unstructured":"Van Der Weijst, L., Y. Lievens, W. Schrauwen, and V. Surmont. 2019. Health-related quality of life in advanced non-small cell lung cancer: A methodological appraisal based on a systematic literature review. Frontiers in Oncology 9: 715. https:\/\/doi.org\/10.3389\/fonc.2019.00715.","journal-title":"Frontiers in Oncology"},{"issue":"5","key":"1954_CR40","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","volume":"15","author":"B van Hout","year":"2012","unstructured":"van Hout, B., M.F. Janssen, Y.S. Feng, T. Kohlmann, J. Busschbach, D. Golicki, et al. 2012. Interim scoring for the EQ-5D-5L: Mapping the EQ-5D-5L to EQ-5D-3L value sets. Value in Health 15 (5): 708\u201315. https:\/\/doi.org\/10.1016\/j.jval.2012.02.008.","journal-title":"Value in Health"},{"key":"1954_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103747","volume":"176","author":"F Waisberg","year":"2022","unstructured":"Waisberg, F., C. Lopez, D. Enrico, A. Rodriguez, I. Hirsch, J. Burton, et al. 2022. Assessing the methodological quality of quality-of-life analyses in first-line non-small cell lung cancer trials: A systematic review. Critical Reviews in Oncology\/Hematology 176: 103747. https:\/\/doi.org\/10.1016\/j.critrevonc.2022.103747.","journal-title":"Critical Reviews in Oncology\/Hematology"},{"key":"1954_CR42","doi-asserted-by":"publisher","unstructured":"Westerink, L., S. Wolters, G. Zhou, A. Postma, C. Boersma, J.F.M. van Boven, et al. 2024. Trends in NICE technology appraisals of non-small cell lung cancer drugs over the last decade. The European Journal of Health Economics, no. 3. https:\/\/doi.org\/10.1007\/s10198-024-01711-0.","DOI":"10.1007\/s10198-024-01711-0"},{"issue":"7","key":"1954_CR43","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1177\/0272989X15587497","volume":"35","author":"TA Young","year":"2015","unstructured":"Young, T.A., C. Mukuria, D. Rowen, J.E. Brazier, and L. Longworth. 2015. Mapping functions in health-related quality of life: Mapping from two cancer-specific health-related quality-of-life instruments to EQ-5D-3L. Medical Decision Making 35 (7): 912\u201326. https:\/\/doi.org\/10.1177\/0272989X15587497.","journal-title":"Medical Decision Making"}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-026-01954-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10198-026-01954-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-026-01954-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:51:10Z","timestamp":1792731070000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10198-026-01954-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":43,"alternative-id":["1954"],"URL":"https:\/\/doi.org\/10.1007\/s10198-026-01954-z","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"LW is currently employed at AstraZeneca, this research has been performed unrelated to her work at AstraZeneca and is part of her PhD research at the University Medical Center Groningen, the Netherlands. MP received grants and honoraria from various pharmaceutical companies, including companies interested in the subject of this paper. JB received consultancy fees, honorarium, and research funding from Aardex, AstraZeneca, Chiesi, GSK, Novartis, Pfizer, Sanofi, Teva, Trudell Medical and Vertex to consult, give lectures, provide advice, and conduct independent research, unrelated to this manuscript and all paid to his institution. CB received grants and honoraria from various pharmaceutical companies, including companies interested in the subject of this paper.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}